GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company focused on developing vaccines and cancer immunotherapies, announced today that its Chairman and CEO, David Dodd, will present at the Noble Capital Markets Twenty-First Annual Emerging Growth Equity Conference (NobleCon21) on December 3, 2025, at 3:00 pm ET. The conference will take place at the Florida Atlantic University Executive Education Complex in Boca Raton, FL.
The presentation, titled "GeoVax Corporate Update," will provide an overview of the company's pipeline, including its lead COVID-19 vaccine candidate, GEO-CM04S1, which is currently in three Phase 2 clinical trials. These trials evaluate GEO-CM04S1 as a primary vaccine for immunocompromised patients, a booster for patients with chronic lymphocytic leukemia (CLL), and a more robust booster for healthy individuals previously vaccinated with mRNA vaccines. In oncology, GeoVax is advancing Gedeptin®, a novel oncolytic solid tumor gene-directed therapy, which recently completed a multicenter Phase 1/2 trial for advanced head and neck cancers.
Additionally, GeoVax is developing a vaccine targeting Mpox and smallpox and, based on recent regulatory guidance, expects to progress directly to a Phase 3 clinical evaluation, bypassing earlier phases. The company holds a strong intellectual property portfolio with worldwide rights to its technologies and product candidates.
Interested investors and guests can attend at a discounted rate by registering here using the discount code GOVXNOBLECON. A high-definition video webcast of the presentation will be available the following day on the Noble Capital Markets’ conference website at www.nobleconference.com and on Channelchek at www.channelchek.com, the investor portal created by Noble. The webcast will be archived for 90 days following the event. Senior GeoVax management will also host one-on-one meetings with registered attendees.
This presentation is significant as it provides an opportunity for investors to gain insights into GeoVax's progress in addressing unmet medical needs, particularly in immunocompromised populations and solid tumor cancers. The company's novel vaccine and therapy approaches could have substantial implications for public health and oncology treatment.
